Articles

Sort by
Previous Page Page 1 of 35 Next Page
  1. Research

    miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an “ALT-like” phenotype in diffuse malignant peritoneal mesothelioma cells

    Understanding the molecular/cellular underpinnings of diffuse malignant peritoneal mesothelioma (DMPM), a fatal malignancy with limited therapeutic options, is of utmost importance for the fruitful management ...

    Graziella Cimino-Reale, Paolo Gandellini, Francesca Santambrogio, Marta Recagni, Nadia Zaffaroni and Marco Folini

    Journal of Hematology & Oncology 2017 10:140

    Published on: 17 July 2017

  2. Research

    Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia

    Current conventional chemotherapy for acute myeloid leukemia (AML) can achieve remission in over 70% of patients, but a majority of them will relapse within 5 years despite continued treatment. The relapse is ...

    Jianbiao Zhou, Chonglei Bi, Ying Qing Ching, Jing-Yuan Chooi, Xiao Lu, Jessie Yiying Quah, Sabrina Hui-Min Toh, Zit-Liang Chan, Tuan Zea Tan, Phyllis SY Chong and Wee-Joo Chng

    Journal of Hematology & Oncology 2017 10:138

    Published on: 11 July 2017

  3. Research

    The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model

    Additional sex combs-like 1 (ASXL1) is frequently mutated in myeloid malignancies. Recent studies showed that hematopoietic-specific deletion of Asxl1 or overexpression of mutant ASXL1

    Yueh-Chwen Hsu, Yu-Chiao Chiu, Chien-Chin Lin, Yuan-Yeh Kuo, Hsin-An Hou, Yi-Shiuan Tzeng, Chein-Jun Kao, Po-Han Chuang, Mei-Hsuan Tseng, Tzu-Hung Hsiao, Wen-Chien Chou and Hwei-Fang Tien

    Journal of Hematology & Oncology 2017 10:139

    Published on: 11 July 2017

  4. Research

    Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

    The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide–dexamethasone (Rd) in pat...

    Jian Hou, Jie Jin, Yan Xu, Depei Wu, Xiaoyan Ke, Daobin Zhou, Jin Lu, Xin Du, Xiequn Chen, Junmin Li, Jing Liu, Neeraj Gupta, Michael J. Hanley, Hongmei Li, Zhaowei Hua, Bingxia Wang…

    Journal of Hematology & Oncology 2017 10:137

    Published on: 6 July 2017

  5. Research

    Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia

    Granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (G-PBSC) has largely replaced unstimulated bone marrow (un-BM) for allografting because of accelerated engraftment, but with ...

    Qian Fan, Hui Liu, Xinquan Liang, Ting Yang, Zhiping Fan, Fen Huang, Yiwen Ling, Xin Liao, Li Xuan, Na Xu, Xiaojun Xu, Jieyu Ye and Qifa Liu

    Journal of Hematology & Oncology 2017 10:135

    Published on: 4 July 2017

  6. Research

    Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

    This study compared the effects of pre-transplantation minimal residual disease (pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched sibling donor transplantation (MSDT) or who r...

    Ying-Jun Chang, Yu Wang, Yan-Rong Liu, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Kai-Yan Liu and Xiao-Jun Huang

    Journal of Hematology & Oncology 2017 10:134

    Published on: 4 July 2017

  7. Review

    MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

    The two murine double minute (MDM) family members MDM2 and MDMX are at the center of an intense clinical assessment as molecular target for the management of cancer. Indeed, the two proteins act as regulators ...

    Veronica Tisato, Rebecca Voltan, Arianna Gonelli, Paola Secchiero and Giorgio Zauli

    Journal of Hematology & Oncology 2017 10:133

    Published on: 3 July 2017

  8. Research

    Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

    Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and re...

    Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne-Rauzy, Moshe Mittelman, Petra Muus, Stephen D. Nimer, Eva Hellström-Lindberg, Bayard L. Powell, Agnes Guerci-Bresler, Mikkael A. Sekeres, H. Joachim Deeg, Consuelo del Cañizo, Peter L. Greenberg, Jamile M. Shammo, Barry Skikne…

    Journal of Hematology & Oncology 2017 10:131

    Published on: 26 June 2017

  9. Research

    Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

    Primary refractory acute myeloid leukemia (PRF-AML) is associated with a dismal prognosis. Allogeneic stem cell transplantation (HSCT) in active disease is an alternative therapeutic strategy. The increased av...

    Eolia Brissot, Myriam Labopin, Matthias Stelljes, Gerhard Ehninger, Rainer Schwerdtfeger, Jürgen Finke, Hans-Jochem Kolb, Arnold Ganser, Kerstin Schäfer-Eckart, Axel R. Zander, Donald Bunjes, Stephan Mielke, Wolfgang A. Bethge, Noël Milpied, Peter Kalhs, Igor-Woflgang Blau…

    Journal of Hematology & Oncology 2017 10:130

    Published on: 24 June 2017

  10. Research

    A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients

    Protein tyrosine phosphatase receptor gamma (PTPRG) is a ubiquitously expressed member of the protein tyrosine phosphatase family known to act as a tumor suppressor gene in many different neoplasms with mechan...

    Marzia Vezzalini, Andrea Mafficini, Luisa Tomasello, Erika Lorenzetto, Elisabetta Moratti, Zeno Fiorini, Tessa L. Holyoake, Francesca Pellicano, Mauro Krampera, Cristina Tecchio, Mohamed Yassin, Nader Al-Dewik, Mohamed A. Ismail, Ali Al Sayab, Maria Monne and Claudio Sorio

    Journal of Hematology & Oncology 2017 10:129

    Published on: 21 June 2017

  11. Research

    Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT

    The feasibility of cord blood transplantation (CBT) in adults is limited by the relatively low number of hematopoietic stem/progenitor cells contained in one single CB unit. The infusion of two CB units from d...

    Frédéric Baron, Annalisa Ruggeri, Eric Beohou, Myriam Labopin, Mohamad Mohty, Didier Blaise, Jan J Cornelissen, Patrice Chevallier, Guillermo Sanz, Eefke Petersen, Bipin N Savani, Eliane Gluckman and Arnon Nagler

    Journal of Hematology & Oncology 2017 10:128

    Published on: 21 June 2017

  12. Research

    Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a novel therapeutic ag...

    Ana-Alicia López-Iglesias, Ana B. Herrero, Marta Chesi, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Irena Misiewicz-Krzeminska, Dalia Quwaider, Montserrat Martín-Sánchez, Daniel Primo, Teresa Paíno, P. Leif Bergsagel, Thomas Mehrling, Marcos González-Díaz, Jesús F. San-Miguel, María-Victoria Mateos…

    Journal of Hematology & Oncology 2017 10:127

    Published on: 20 June 2017

  13. Rapid communication

    Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

    MDM2 and CDK4 are frequently co-amplified in well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS). We aimed to determine whether combined MDM2/CDK4 targeting is associated wi...

    Audrey Laroche-Clary, Vanessa Chaire, Marie-Paule Algeo, Marie-Alix Derieppe, François L. Loarer and Antoine Italiano

    Journal of Hematology & Oncology 2017 10:123

    Published on: 19 June 2017

  14. Research

    MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway

    Brain metastasis (BM) is associated with poor prognosis in patients with non-small cell lung cancer (NSCLC). Recent studies demonstrated that microRNA-330-3p (miR-330-3p) was involved in NSCLC brain metastasis...

    Chun-Hua Wei, Gang Wu, Qian Cai, Xi-Can Gao, Fan Tong, Rui Zhou, Rui-Guang Zhang, Ji-Hua Dong, Yu Hu and Xiao-Rong Dong

    Journal of Hematology & Oncology 2017 10:125

    Published on: 19 June 2017

  15. Research

    Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia

    T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) and programmed cell death protein 1 (PD-1) are important inhibitory receptors that associate with T cell exhaustio...

    Liuluan Zhu, Yaxian Kong, Jianhong Zhang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Neil D. Palmisiano, Ming Wang, Bei Jia, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hui Zeng and Hong Zheng

    Journal of Hematology & Oncology 2017 10:124

    Published on: 19 June 2017

  16. Research

    Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases

    Lymphatic metastasis is one of the leading causes of death in patients with different types of cancer and is the main prognostic factor for the disease survival. The formation of new lymphatic vessels (lymphan...

    Melissa García-Caballero, Jenny Paupert, Silvia Blacher, Maureen Van de Velde, Ana Rodríguez Quesada, Miguel Angel Medina and Agnès Noël

    Journal of Hematology & Oncology 2017 10:122

    Published on: 19 June 2017

  17. Research

    Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes

    C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients...

    Michela Sica, Tommaso Rondelli, Patrizia Ricci, Maria De Angioletti, Antonio M. Risitano and Rosario Notaro

    Journal of Hematology & Oncology 2017 10:126

    Published on: 19 June 2017

  18. Review

    Role of epigenetics-microRNA axis in drug resistance of multiple myeloma

    Despite administration of novel therapies, multiple myeloma (MM) remains incurable with resistance to drugs leading to relapse in most patients. Thus, it is critical to understand the detailed mechanisms under...

    Nasrin Rastgoo, Jahangir Abdi, Jian Hou and Hong Chang

    Journal of Hematology & Oncology 2017 10:121

    Published on: 17 June 2017

  19. Research

    Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation

    Impaired T cell reconstitution remains a major deterrent in the field of bone marrow (BM) transplantation (BMT) due to pre-conditioning-induced damages inflicted to the thymi of recipient hosts. Given the prev...

    Aurélie Tormo, Fatemeh Khodayarian, Yun Cui, Edouard Al-Chami, Reem Kanjarawi, Beatriz Noé, Huijie Wang and Moutih Rafei

    Journal of Hematology & Oncology 2017 10:120

    Published on: 14 June 2017

  20. Research

    Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

    In B cell non-Hodgkin lymphoma (B-NHL), rituximab-containing reduced-intensity conditioning regimens (R-RIC) have been shown to provide favorable outcomes in single-arm studies; however, large multicenter stud...

    Narendranath Epperla, Kwang Woo Ahn, Sairah Ahmed, Madan Jagasia, Alyssa DiGilio, Steven M. Devine, Samantha Jaglowski, Vanessa Kennedy, Andrew R. Rezvani, Sonali M. Smith, Anna Sureda, Timothy S. Fenske, Mohamed A. Kharfan-Dabaja, Phillipe Armand and Mehdi Hamadani

    Journal of Hematology & Oncology 2017 10:117

    Published on: 12 June 2017

  21. Letter to the Editor

    T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells

    Patients with B cell lymphomas bearing MYC translocation combined with translocation involving other genes, such as BCL2, BCL3, or BCL6, defined as double-hit lymphoma (DHL), have a poor prognosis. Recent studies...

    Keichiro Mihara, Tetsumi Yoshida, Yoshifumi Takei, Naomi Sasaki, Yoshihiro Takihara, Junya Kuroda and Tatsuo Ichinohe

    Journal of Hematology & Oncology 2017 10:116

    Published on: 8 June 2017

Previous Page Page 1 of 35 Next Page
JHO logo

Advertisement